Session » Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2083

A Novel Scoring System to Predict a Cancer Development in Patients with Idiopathic Inflammatory Myopathy

10:30AM-12:30PM: Abstract Number: 2075

A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD)

10:30AM-12:30PM: Abstract Number: 2058

Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome: An Analysis of the CLASS Project Database

10:30AM-12:30PM: Abstract Number: 2061

Associations Between Intramyocellular Lipid and Muscle Function in Patients with Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2069

Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort

10:30AM-12:30PM: Abstract Number: 2067

Clinical and Laboratory Characterization of Overlap Connective Tissue Disease in Patients with Idiopathic Inflammatory Myopathies: Results from the MYOTReCSZ Cohort

10:30AM-12:30PM: Abstract Number: 2072

Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy

10:30AM-12:30PM: Abstract Number: 2060

Clustering Analysis of Immune Cell Subtypes and Clinical Phenotypes in Idiopathic Inflammatory Myopathy

10:30AM-12:30PM: Abstract Number: 2066

Comparative Diagnostic Efficacy of Quantitative Measurement of Echo Intensity and Texture versus Qualitative Analysis of Ultrasound Images in Myositis

10:30AM-12:30PM: Abstract Number: 2076

Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience

10:30AM-12:30PM: Abstract Number: 2077

Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts

10:30AM-12:30PM: Abstract Number: 2082

Different Clinical Phenotypes of Patients with Anti-synthetase Syndrome: Unsupervised Cluster Analysis in the CLASS Database

10:30AM-12:30PM: Abstract Number: 2084

Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study

10:30AM-12:30PM: Abstract Number: 2074

Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy

10:30AM-12:30PM: Abstract Number: 2080

HLA-DRB1*11:01 Association Differenciates Anti-hmgcr Immune-mediated Necrotizing Myopathy from Non-immune Mediated Statin Myotoxicity

10:30AM-12:30PM: Abstract Number: 2070

Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients

10:30AM-12:30PM: Abstract Number: 2078

Increased RAGE Expression in Myositis

10:30AM-12:30PM: Abstract Number: 2062

Performance of the Patient Self-Assessment Tools for Cutaneous Dermatomyositis: Patient CDASI and Rash Mapping

10:30AM-12:30PM: Abstract Number: 2068

Poloxamers 188 & 182 Are Effective in Repairing the Membrane Resealing Defect in Myositis

10:30AM-12:30PM: Abstract Number: 2065

Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)

10:30AM-12:30PM: Abstract Number: 2081

Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 2064

Quantifying Cutaneous Dermatomyositis: A Novel 3D Image-based Approach

10:30AM-12:30PM: Abstract Number: 2071

Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset

10:30AM-12:30PM: Abstract Number: 2063

Serum Glutamate Dehydrogenase in Idiopathic Inflammatory Myopathy Patients

10:30AM-12:30PM: Abstract Number: 2086

Specific Transcriptomic Profile Associated with Disease Activity in Muscle Biopsies from Patients with Sarcoid Myopathy

10:30AM-12:30PM: Abstract Number: 2085

The Effects of Pioglitazone on Metabolic Dysregulation in Inclusion Body Myositis: An Open-Label Pilot Study

10:30AM-12:30PM: Abstract Number: 2059

The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome

10:30AM-12:30PM: Abstract Number: 2073

Ultrasound Findings of Activity in Patients with Inflammatory Myopathies and Clinical and Laboratory Comparison

10:30AM-12:30PM: Abstract Number: 2079

Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].